Intellipharmaceutics International has received approximately $3.1 million under its licensing agreement with Par Pharmaceutical as its first payment relating to commercial sales of ADHD treatment dexmethylphenidate hydrochloride extended-release capsules. The payment represents its share of profits for the 15 and 30 mg strengths of the drug for the period beginning November 19, 2013 and ending December 31, 2013. Future profit-share payments are expected on a quarterly basis.   As the first-file...